Published in Circ Res on July 22, 2010
Effect of Migalastat on Cardiac Involvement in Fabry Disease (MAIORA) | NCT03838237
MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 4.39
MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol (2012) 3.78
Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64
MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med (2014) 2.62
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J (2013) 2.02
Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol (2013) 1.84
Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res (2012) 1.78
In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet (2011) 1.69
Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol (2013) 1.69
Diabetes complications: the microRNA perspective. Diabetes (2011) 1.60
MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One (2011) 1.60
MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications. Diabetes (2011) 1.56
Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood (2015) 1.56
MicroRNA in ischemic stroke etiology and pathology. Physiol Genomics (2010) 1.48
Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res (2011) 1.47
miR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway. Curr Vasc Pharmacol (2016) 1.42
microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med (2011) 1.39
Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One (2012) 1.37
A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS One (2014) 1.35
Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med (2014) 1.34
MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol (2013) 1.33
Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res (2011) 1.30
Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer (2013) 1.28
MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med (2011) 1.28
Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther (2012) 1.27
Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One (2013) 1.24
MicroRNAs in adipogenesis and as therapeutic targets for obesity. Expert Opin Ther Targets (2011) 1.22
MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol (2015) 1.20
Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med (2012) 1.20
Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One (2011) 1.18
The Intestinal Transport of Bovine Milk Exosomes Is Mediated by Endocytosis in Human Colon Carcinoma Caco-2 Cells and Rat Small Intestinal IEC-6 Cells. J Nutr (2015) 1.17
Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb J (2012) 1.17
Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res (2012) 1.17
Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res (2013) 1.17
MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovasc Res (2011) 1.15
miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol (2011) 1.15
Muscle-enriched microRNA miR-486 decreases in circulation in response to exercise in young men. Front Physiol (2013) 1.13
Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infect Dis (2012) 1.13
MicroRNAs as potential signatures of environmental exposure or effect: a systematic review. Environ Health Perspect (2015) 1.13
miR-191: an emerging player in disease biology. Front Genet (2014) 1.12
Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One (2011) 1.12
Roles of microRNA on cancer cell metabolism. J Transl Med (2012) 1.11
MicroRNAs in insulin resistance and obesity. Exp Diabetes Res (2012) 1.10
Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood (2013) 1.10
Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep (2015) 1.06
Circulating inflamma-miRs in aging and age-related diseases. Front Genet (2013) 1.06
MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc (2014) 1.05
MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms. Circ Res (2013) 1.02
MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med (2011) 1.01
miR-320 Regulates Glucose-Induced Gene Expression in Diabetes. ISRN Endocrinol (2012) 1.01
MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes (2014) 1.01
The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int J Mol Sci (2014) 1.00
MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci (2013) 0.99
Temporal microRNA expression during in vitro myogenic progenitor cell proliferation and differentiation: regulation of proliferation by miR-682. Physiol Genomics (2010) 0.99
Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol (2014) 0.99
Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging (Albany NY) (2014) 0.99
Diminished skeletal muscle microRNA expression with aging is associated with attenuated muscle plasticity and inhibition of IGF-1 signaling. FASEB J (2014) 0.98
Glycoproteomic analysis of the secretome of human endothelial cells. Mol Cell Proteomics (2013) 0.98
Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol (2012) 0.98
MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond) (2014) 0.98
MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond) (2015) 0.98
Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease. Cardiovasc Diabetol (2014) 0.96
Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci (2013) 0.96
Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J (2014) 0.96
Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. Biomed Res Int (2013) 0.96
Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS One (2014) 0.95
MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol Ther (2013) 0.95
Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment. Cardiovasc Diabetol (2014) 0.95
MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis (2014) 0.95
Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS One (2013) 0.94
Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor β2 (TGF-β2) pathways. J Biol Chem (2013) 0.93
Circulating microRNAs are not eliminated by hemodialysis. PLoS One (2012) 0.93
MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacol Res (2013) 0.92
Circulating microRNAs as biomarkers of acute stroke. Int J Mol Sci (2014) 0.92
Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J (2012) 0.92
Integrative miRNA-mRNA profiling of adipose tissue unravels transcriptional circuits induced by sleep fragmentation. PLoS One (2012) 0.92
Control of mitochondrial activity by miRNAs. J Cell Biochem (2012) 0.92
Urinary microRNA-10a and microRNA-30d serve as novel, sensitive and specific biomarkers for kidney injury. PLoS One (2012) 0.92
Association of the genetic polymorphisms in pre-microRNAs with risk of ischemic stroke in a Chinese population. PLoS One (2015) 0.92
Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol (2014) 0.91
Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes. Clin Transl Sci (2011) 0.91
Identification of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and qPCR-based profiling platforms. BMC Genomics (2014) 0.91
DNA damage and repair in atherosclerosis: current insights and future perspectives. Int J Mol Sci (2012) 0.90
Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis. Hum Reprod (2012) 0.90
Genome-wide expression patterns in physiological cardiac hypertrophy. BMC Genomics (2010) 0.89
Human vascular endothelial cells transport foreign exosomes from cow's milk by endocytosis. Am J Physiol Cell Physiol (2016) 0.89
Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm Res (2013) 0.89
microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol Res (2014) 0.89
Circulating miRNAs in ageing and ageing-related diseases. J Genet Genomics (2014) 0.89
Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) (2013) 0.89
MicroRNAs in Vascular Biology. Int J Vasc Med (2012) 0.89
miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cells. BMC Genomics (2013) 0.88
Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res Notes (2013) 0.88
Transcriptomic biomarkers of cardiovascular disease. Prog Cardiovasc Dis (2012) 0.88
Post-transcriptional regulation in metabolic diseases. RNA Biol (2012) 0.88
Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clin Epigenetics (2015) 0.88
All's well that transcribes well: non-coding RNAs and post-stroke brain damage. Neurochem Int (2013) 0.88
MicroRNAs as pharmacological targets in diabetes. Pharmacol Res (2013) 0.88
Systems Epidemiology: A New Direction in Nutrition and Metabolic Disease Research. Curr Nutr Rep (2013) 0.87
MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell (2012) 0.87
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 7.12
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol (2012) 5.12
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Telomere length and risk of incident cancer and cancer mortality. JAMA (2010) 3.55
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes (2004) 2.89
Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay. Int J Epidemiol (2009) 2.87
Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer (2008) 2.72
Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging (2013) 2.72
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol (2008) 2.56
Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood (2009) 2.40
Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke (2006) 2.31
Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology (2013) 2.28
Prevalence and significance of an isolated long QT interval in elite athletes. Eur Heart J (2007) 2.28
Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res (2011) 2.26
Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res (2002) 2.25
Circulating microRNAs as novel biomarkers for platelet activation. Circ Res (2013) 2.22
Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology (2012) 2.19
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest (2014) 2.06
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care (2007) 2.03
Smooth muscle cells in transplant atherosclerotic lesions are originated from recipients, but not bone marrow progenitor cells. Circulation (2002) 2.02
Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation (2002) 1.97
Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res (2010) 1.96
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging (2014) 1.92
Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care (2003) 1.88
Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin. Circ Res (2010) 1.87
Soluble RANKL and risk of nontraumatic fracture. JAMA (2004) 1.83
Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res (2013) 1.81
Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol (2010) 1.81
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
Marburg I polymorphism of factor VII--activating protease: a prominent risk predictor of carotid stenosis. Circulation (2003) 1.77
Ethnic differences in left ventricular remodeling in highly-trained athletes relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 1.74
A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res (2009) 1.72
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res (2004) 1.72
Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet (2011) 1.72